Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients

X-linked hypophosphataemia (XLH) is a life-long phosphate-wasting disorder that causes skeletal deformities, pain, stiffness, and fatigue and impairs quality of life. Burosumab was approved for use in adults in 2020. We describe three adults with persistent XLH symptoms who received burosumab treatm...

Full description

Saved in:
Bibliographic Details
Main Authors: Julia Day, Chandrin Jayatilleke, Matthew Roy
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Bone Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187224000810
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846151834278821888
author Julia Day
Chandrin Jayatilleke
Matthew Roy
author_facet Julia Day
Chandrin Jayatilleke
Matthew Roy
author_sort Julia Day
collection DOAJ
description X-linked hypophosphataemia (XLH) is a life-long phosphate-wasting disorder that causes skeletal deformities, pain, stiffness, and fatigue and impairs quality of life. Burosumab was approved for use in adults in 2020. We describe three adults with persistent XLH symptoms who received burosumab treatment in a real-world setting. Patients report improvements in pain, mobility, physical function, energy, fatigue, and mental wellbeing through patient-reported outcome measures, enriched with further detail from written testimonials.
format Article
id doaj-art-64547b4b26184dd7ac6d3097478f722a
institution Kabale University
issn 2352-1872
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Bone Reports
spelling doaj-art-64547b4b26184dd7ac6d3097478f722a2024-11-27T05:02:48ZengElsevierBone Reports2352-18722024-12-0123101814Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patientsJulia Day0Chandrin Jayatilleke1Matthew Roy2Department of Rheumatology, Bristol Royal Infirmary, Bristol, BS2 8HW, UK; Corresponding author.Department of Rheumatology, Royal United Hospital, Bath BA1 3NG, UKDepartment of Rheumatology, Bristol Royal Infirmary, Bristol, BS2 8HW, UKX-linked hypophosphataemia (XLH) is a life-long phosphate-wasting disorder that causes skeletal deformities, pain, stiffness, and fatigue and impairs quality of life. Burosumab was approved for use in adults in 2020. We describe three adults with persistent XLH symptoms who received burosumab treatment in a real-world setting. Patients report improvements in pain, mobility, physical function, energy, fatigue, and mental wellbeing through patient-reported outcome measures, enriched with further detail from written testimonials.http://www.sciencedirect.com/science/article/pii/S2352187224000810BurosumabPatient-reported outcomeCase seriesEarly accessX-linked hypophosphatemia
spellingShingle Julia Day
Chandrin Jayatilleke
Matthew Roy
Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
Bone Reports
Burosumab
Patient-reported outcome
Case series
Early access
X-linked hypophosphatemia
title Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
title_full Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
title_fullStr Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
title_full_unstemmed Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
title_short Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients
title_sort improvements with burosumab treatment in an early access programme for adults with x linked hypophosphataemia a case series of three patients
topic Burosumab
Patient-reported outcome
Case series
Early access
X-linked hypophosphatemia
url http://www.sciencedirect.com/science/article/pii/S2352187224000810
work_keys_str_mv AT juliaday improvementswithburosumabtreatmentinanearlyaccessprogrammeforadultswithxlinkedhypophosphataemiaacaseseriesofthreepatients
AT chandrinjayatilleke improvementswithburosumabtreatmentinanearlyaccessprogrammeforadultswithxlinkedhypophosphataemiaacaseseriesofthreepatients
AT matthewroy improvementswithburosumabtreatmentinanearlyaccessprogrammeforadultswithxlinkedhypophosphataemiaacaseseriesofthreepatients